What Is Repconex Gene (利普康基因) and What Genetic Testing Services Does It Offer?

Repconex Gene (利普康基因) is the consumer-facing name of Beijing Repconex Biotechnology Co., Ltd. (北京利普康生物科技有限公司), a Beijing-based biotech company founded in March 2009 by a group of US-trained PhDs. It positions itself not as a sequencing lab first, but as a genetic big-data analysis and health-management company: it takes sequencing data produced by itself or by partner labs and turns it into interpreted reports for individuals, hospitals, and institutions. If you are looking for a company that analyzes and explains genetic data — especially for disease risk, tumor treatment guidance, and medication safety — that is the core of what it does. If you need a company whose main selling point is raw sequencing throughput or consumer ancestry entertainment, this is a different kind of provider.

What the company actually does

The site describes three service pillars, which map cleanly onto three customer types.

1. Data analysis (基因大数据)

Repconex accepts and interprets several data types:

• Whole-genome sequencing data (WGS)
• Whole-exome sequencing data (WES)
• High-throughput microarray data (compatible with mainstream chips)
• Targeted-capture gene variant data

Its stated differentiators are a self-developed database focused on Asian populations — collecting published findings on gene–disease, gene–trait, and gene–drug-response relationships for East Asian people — plus automated software for database syncing, data mining, and report generation, for which it holds software copyright registrations. The company says it has provided analysis and interpretation services to multiple sequencing labs, including Shanghai Southern Gene Technology (上海南方基因科技有限公司).

2. Clinical guidance (临床指导)

This line centers on tumor targeted-drug testing and liquid biopsy. Using high-throughput sequencing plus multiple analysis pipelines, Repconex analyzes tumor-related gene variants to produce individualized reports intended to help physicians select targeted drugs and assess chemotherapy toxicity. The site states the company has cooperated with medical institutions across China. Note the framing: the report is positioned as decision support for doctors, not as a standalone diagnosis.

3. Health management (健康管理)

For healthy people, the company offers risk-warning solutions: a personalized genetic report covering inherited disease predisposition, individual traits, and drug-response assessment, paired with what it calls a digital disease-risk profile and an individualized health-management plan. The site claims this service has reached roughly 100,000 users across nearly 10 large insurance groups and more than 300 institutions.

Product areas and technology stack

The current product portfolio is described as covering:

Supporting infrastructure includes the RGTS (Repconex Gene Test System) analysis platform, which received a national technology-innovation fund grant and software copyright certificates in 2015, and a Cancer Genome Analysis system completed in August 2016 for NGS-based tumor targeted-drug testing. The company was first certified as a National High-Tech Enterprise (国家高新技术企业) in 2015 and passed recertification in 2025.

Who it is built for

• Individuals wanting inherited disease-risk information, trait insights, or medication-response guidance.
• Hospitals and physicians needing tumor variant interpretation to support targeted-therapy and chemotherapy decisions.
• Insurers and institutions (the site cites nearly 10 large insurance groups and 300+ institutions) embedding genetic risk assessment into health-management programs.
• Sequencing labs that need a third-party interpretation and reporting layer.

Company background and credibility signals

• Founded March 2009; described as an early domestic player focused on big-data analysis in the biotech sector.
• Founder Han Chunsheng (韩春生): postdoctoral fellow at Johns Hopkins Bloomberg School of Public Health, with prior clinical posts at Beijing Friendship Hospital and Beijing Haidian Hospital oncology department.
• The database and analysis-model architecture is attributed to a researcher who is a doctoral supervisor at the Chinese Academy of Sciences, long active in bioinformatics, drug-target mining, and gene-sequence analysis.
• Timeline highlights: 2010 launched a personal whole-genome testing product in Asia; 2011 began cooperation with the National Engineering Research Center for Biochips / Shanghai Southern Gene; 2013 launched consumer disease-susceptibility testing; 2014 passed 100 partner institutions; 2016 completed the cancer genome analysis system.

How to engage

The website (dna111.com) provides login and registration entry points alongside sections for solutions, company introduction, business cooperation, service cases, careers, and contact. The site does not publish pricing, so costs must be obtained by contacting the company or a partner institution directly. For clinical testing, the practical route is through a cooperating hospital or physician rather than self-service.

Practical caveats

• The site's claims about user numbers, partner counts, and institutional reach are company statements; treat them as marketing figures rather than independently verified data.
• Genetic risk reports describe predisposition, not certainty — a "risk warning" is not a diagnosis, and clinical decisions should run through a qualified physician.
• Because pricing and turnaround times are not listed, compare quotes and confirm what data type and report scope you are actually buying before committing.
• If your goal is tumor treatment selection, confirm that the specific test covers the variants relevant to your cancer type and that your oncologist will use the report.